National Bank of Canada FI Raises Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 43.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 378,247 shares of the life sciences company's stock after acquiring an additional 114,834 shares during the quarter. National Bank of Canada FI owned 0.24% of Illumina worth $52,050,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Illumina during the third quarter worth $30,000. VisionPoint Advisory Group LLC grew its stake in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after purchasing an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $37,000. Gradient Investments LLC raised its position in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company's stock worth $40,000 after purchasing an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. lifted its holdings in Illumina by 183.0% during the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company's stock worth $42,000 after buying an additional 194 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the business's stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. Stephens reiterated an "overweight" rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating in a report on Tuesday, January 16th. Scotiabank dropped their target price on shares of Illumina from $185.00 to $176.00 and set a "sector outperform" rating for the company in a research report on Monday. Finally, OTR Global restated a "mixed" rating on shares of Illumina in a research report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of "Hold" and a consensus target price of $164.65.

Illumina Stock Up 0.9 %

NASDAQ:ILMN traded up $1.05 on Monday, hitting $118.98. 1,803,169 shares of the company's stock were exchanged, compared to its average volume of 1,713,389. The company has a market cap of $18.95 billion, a P/E ratio of -14.60 and a beta of 1.20. The firm has a 50-day moving average price of $129.67 and a 200-day moving average price of $127.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $213.91.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the company earned $0.08 earnings per share. The business's revenue was down 1.0% compared to the same quarter last year. As a group, analysts expect that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.